Literature DB >> 19776034

Global and regional causes of death.

Colin D Mathers1, Ties Boerma, Doris Ma Fat.   

Abstract

BACKGROUND: Assessing the causes of death across all regions of the world requires a framework for integrating, and analysing, the fragmentary information that is available on numbers of deaths and their cause distributions. This paper provides an overview of the met and methods used by the World Health Organization to develop global-, regional- and country-level estimates of mortality for a comprehensive set of causes, and provides an overview of global and regional levels and patterns of causes of death for the year 2004. The paper also examines some of the data gaps, uncertainties and limitations in the resulting mortality estimates. SOURCES OF DATA: Deaths for 136 disease and injury causes were estimated from available death registration data (111 countries), sample death registration data (India and China), and for the remaining countries from census and survey information, and cause-of-death models. Population-based epidemiological studies and notifications systems also contributed to estimating mortality for 21 of these causes (representing 28% of deaths globally, 58% in Africa). AREAS OF AGREEMENT: Ischaemic heart disease and cerebrovascular disease are the leading causes of death, followed by lower respiratory infections, chronic obstructive pulmonary disease and diarrhoeal diseases. AIDS and TB are the sixth and seventh most common causes of death, respectively, lower than in previous estimates. One-half of all child deaths are from four preventable and treatable communicable diseases. Globally, around 6 in 10 deaths are from non-communicable diseases, 3 from communicable diseases and 1 from injuries. Injury mortality is highest in South-East Asia, Latin America and the Eastern Mediterranean region. These results illustrate continuing huge disparities in risks and causes of death across the world. AREAS OF CONTROVERSY: Global mortality analyses of the type reported here have been criticized for making estimates of mortality for regions with limited, incomplete and uncertain data. Estimates presented here use a range of techniques depending on the type and quality of evidence. Better evidence on levels of adult mortality is needed for African countries. GROWING POINTS: Considerable gaps and deficiencies remain in the information available on causes of death. Nine of 10 deaths in 2004 occurred in low- and middle-income countries, reinforcing the fundamental importance of improving mortality statistics as a measure of health status in the developing world. Acknowledging the controversies around use of incomplete and uncertain data, systematic assessments and synthesis of the available evidence will continue to provide important inputs for global health planning. AREAS TIMELY FOR DEVELOPING RESEARCH: Innovative methods involving sample registration, and the use of verbal autopsy questionnaires in surveys, are needed to address these gaps. Research on strategies to improve comparability of cause-of-death certification and coding practices across countries is also a high priority.

Entities:  

Mesh:

Year:  2009        PMID: 19776034     DOI: 10.1093/bmb/ldp028

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  197 in total

1.  Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients.

Authors:  Deepti Malhotra; Rajesh K Thimmulappa; Nicolas Mercado; Kazuhiro Ito; Ponvijay Kombairaju; Sarvesh Kumar; Jinfang Ma; David Feller-Kopman; Robert Wise; Peter Barnes; Shyam Biswal
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

2.  Implementation of an in-patient pediatric mortality reduction intervention, Gondar University Hospital, Ethiopia.

Authors:  D M Gordon; A Shehibo; A Tazebew; M R Huddart; A Kadir; N Allen; H Draper; M Kokeb
Journal:  Public Health Action       Date:  2014-12-21

3.  [Development of mortality and morbidity of vascular diseases: variations between coronary heart disease and stroke].

Authors:  P U Heuschmann; H K Neuhauser; M Endres
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

4.  Tendency for age-specific mortality with hypertension in the European Union from 1980 to 2011.

Authors:  Lichan Tao; Cunying Pu; Shutong Shen; Hongyi Fang; Xiuzhi Wang; Qinkao Xuan; Junjie Xiao; Xinli Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Predominant Mycobacterium tuberculosis Families and High Rates of Recent Transmission among New Cases Are Not Associated with Primary Multidrug Resistance in Lima, Peru.

Authors:  Francesca Barletta; Larissa Otero; Bouke C de Jong; Tomotada Iwamoto; Kentaro Arikawa; Patrick Van der Stuyft; Stefan Niemann; Matthias Merker; Cécile Uwizeye; Carlos Seas; Leen Rigouts
Journal:  J Clin Microbiol       Date:  2015-03-25       Impact factor: 5.948

6.  Quality of life and physical activity among adults: population-based study in Brazilian adults.

Authors:  Gabrielle Pucci; Rodrigo S Reis; Cassiano R Rech; Pedro C Hallal
Journal:  Qual Life Res       Date:  2012-02-24       Impact factor: 4.147

7.  Why is controlling blood pressure after stroke so difficult?

Authors:  Martin Dawes
Journal:  CMAJ       Date:  2012-11-19       Impact factor: 8.262

8.  Socio-demographic, behavioral, and health correlates of nutrition transition dietary indicators in San Juan, Puerto Rico.

Authors:  Uriyoán Colón-Ramos; Cynthia M Pérez-Cardona; Rafael Monge-Rojas
Journal:  Rev Panam Salud Publica       Date:  2013-11

9.  Protective effect of CDP-choline on ischemia-reperfusion-induced myocardial tissue injury in rats.

Authors:  C Coskun; B Avci; M Yalcin; A Yermezler; M S Yilmaz; V Savci
Journal:  Ir J Med Sci       Date:  2013-11-29       Impact factor: 1.568

10.  Post-stroke infections exacerbate ischemic brain injury in middle-aged rats: immunomodulation and neuroprotection by progesterone.

Authors:  S Yousuf; F Atif; I Sayeed; J Wang; D G Stein
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.